The financial crisis currently spreading around the world has been felt by all industries. The pharma outsourcing industry is not immune to that. A much softer demanding for outsourcing has been felt by the industry since the third quarter of 2008. And it is expected that such a soft demanding will remain at least throughout the first half of 2009 and may even extend to 2010. Many CROs/CMOs around the world have been reducing their earning forecasts of 2008 and even 2009 as well. For example, Charles River Laboratories recently reduced its full year (2008) outlook by 3%. Similarly, Lonza recently also stated that it would miss its full year earning targets mainly due to the postponement and/or cancellation of the projects originally booked by customers
In last couple of years China has been the primary choice of destination for outsourcing for a number of reasons. And Chinese pharma outsourcing industry has been thus growing in an exponential rate during this time period. For example, according to JZMed, in the last three years (2005-2007) the Chinese pharma outsourcing industry had grown in an average annual rate of ca. 87% (Please see Figure 1 for market development of the industry). By the end of 2007 the total market size of the industry has already reached more than $1 B.
Although demanding for outsourcing in China is still relatively high at this moment, a slowdown has been seen. For example, in its 2008 3Q earning report WuXi PharmaTech reported a slight decrease in outsourcing demand. Its 2008 3Q earning was 6% shorter than expected. The company had thus reduced the forecast of its year 2008 service revenue from originally expected $300 M to now about $265 M, about 12% lower than expected, indicating that there might be even softer demanding for its service in the last quarter of 2008.
On the surface of the impact of the current financial crisis on pharma outsourcing to China, a growth slowdown might be inevitable in the next 1-2 years. However, the degree to which each service sector is affected by the crisis might actually vary as several factors, both positive and negative, are knitted together. These factors include the change of outsourcing by both major pharma and small biotech companies. A positive impact on pharma outsourcing to China might also be possible due to the latest terror attack at Mumbai of India as it may cause some drug companies to change their mind of outsourcing destinations.
Change of outsourcing by major pharma companies
To those major pharma/biotech companies who mostly have drug products on market, outsourcing to China or collaborating with Chinese counterparts is a two-facet story: both to reduce cost and to market their drug products in the country. The latter has, however, been the main driving force as China’s potentially huge drug market is so attractive.
Due to strong cash reserves, almost none of the major pharma/biotech companies have been affected at present by the financial crisis. Rather, their drug pipelines would have become enriched as they are currently posed to acquire more drug candidates from those small biotech companies that are cash poor and thus forced to give up their ownership (please see below for more discussions). The best example is the latest acquisitions by BMS of two late stage cancer drug candidates, XL184 and XL281, from Exelixis which announced to reduce 10% of its workforce just one month prior to the acquisition.
It is anticipated that in near future outsourcing to China by these major pharma companies will still remain strong and even no apparent changes would be felt. The only difference might be the category of the outsourcing projects. As these major companies will now have more drug candidates in various development stages, they will certainly place more efforts on development rather than on discovery. It is therefore anticipated that, while less outsourcing in early stage drug discovery might be likely, more outsourcing in late stage drug development by these major companies will certainly take place in near future (please also see below for more discussions).
Change of outsourcing by small biotech companies
In fact, the significant decrease in outsourcing demanding is from the small even medium-sized biotech companies. For example, both Lonza and WuXi PharmaTech reported that many projects originally booked but recently postponed or cancelled were from small biotech customers.
It seems that those small biotech companies, in particular those still in early stage drug discovery and development, hit hardest by the financial crisis. For example, according to JZMed, in the two months of last October and November alone, more than twenty five biotech companies had announced cuts of their workforce. The percentage of job cuts within these companies ranged from 5% only to more than 75%. A number of biotech companies also announced to reprioritize their R&D programs with more focuses only on late stage development. Several of them even completely cut early stage programs including those still in discovery and preclinical research. Some even planned to close their R&D facilities or put up their programs on idle.
At this moment, most small biotech companies that are cash poor have to seriously think about how they could survive the financial crisis as many VCs are at present not favoring investing in small biotechs. Most people in the industry believe that there are two options for these cash-short small biotech companies to consider at this moment:
(1) Selling their drug candidates or even their entire company to those major ones with a significant discount.
(2) Outsourcing their R&D projects to low cost areas such as China so that they could still continue their programs even with a minimum cash reserve.
The first option works only to those companies that have developed a series of lead compounds. Some of them must have entered development stages and showed promising results. To those that are still in discovery stage or early preclinical development stage, the current situation is extremely difficult as some VCs who have invested in startups or early stage biotech companies are currently selling their stakes in a marginal discount of as low as 10-60% of their original investment price. To these companies the second option would thus become critically important and could be the best choice. Therefore, outsourcing to China by these cash-poor small biotech companies might increase in near future.
Impact of terror attack at Mumbai on outsourcing to China
The terror attack happened at Mumbai in late last November would likely have a negative impact on India’s booming pharma outsourcing industry, at least in near term. Although Mumbai is only an economy center of India, not a biotech hub, the incident will very likely drive away some Western companies from doing business in the country. Although it is still too early to estimate the long term effect, the impact will be most felt in the following 6-12 moths. For those companies that currently have projects in India, they might scale them down or re-evaluate the feasibility of their Indian operation. For those that have previously planned outsourcing to India, they may change their mind now. The situation, however, might exert a positive impact on China pharma outsourcing as some drug companies may now pick up China as an alternative. Figure 2 summarized these effects.
How each pharma outsourcing sector affected
The financial crisis has exerted a complicated net effect on the pharma outsourcing to China. Based on our latest studies on this Chinese industry, we reached following conclusions about the possible impacts on each segment of the entire outsourcing value chain.
1. Impact on early stage drug discovery
As almost all small biotech companies that are financially troubled are cutting all early stage research activities, and as major pharma and biotech companies will become more focused on late stage development, it is expected that worldwide outsourcing in early stage drug discovery, including outsourcing to China, will very likely decrease dramatically in the near future.
However, the actual situation may vary in particular for outsourcing to China. As discussed earlier, those cash-poor biotech companies that are still in discovery stage or early development stage may be forced to consider outsourcing to China in order to survive from this tough time. In the past this option would not be considered by these small biotech companies. But the abrupt change in the financial and investment environment will force them to change their mind. So outsourcing demand in drug discovery by some of these early stage drug companies might slightly offset the otherwise declining trend.
2. Impact on preclinical development
A similar effect would likely be expected on the preclinical research sector. The reasons are as follows:
(1) In the past the big pharma and biotech companies were hungry hunting all types of drug candidates even including those still in preclinical development stage. However, as they now have more choices, those still in preclinical development stage will become less attractive to them.
(2) Most cash-short biotech companies are also cutting their programs still in preclinical research stage as they are still far away from the valuable, final product stage.
(3) On the other hand, those small biotech companies that otherwise would not consider outsourcing to China may now consider this option. Some of them may be able to continue their R&D programs with their current cash reserve if they opt to operate them in China as it would cost them much less.
3. Impact on outsourcing of clinical research
Clinical research is the most costly part in the entire value chain of drug R&D. But it is also the most valuable part as it is closest to the final product stage. It seems that even under the financial crisis most biotech companies will still remain focused on the clinical development research. The degree of their focuses varies, still depending on how much cash reserves each has on hand. Most companies cut early stage clinical research such as phase I trial and focus on the middle stage such as phase II. As for phase III trial, because it is the most expensive research, some companies just suspend it and seek co-development with a big pharma or biotech company.
On the other hand, outsourcing of clinical research to China by those major companies will very likely increase. The reasons were just stated earlier. So the net effect of the current financial crisis on China’s pharma outsourcing in this sector may be positive instead.
4. Impact on contract manufacturing
Contract manufacturing of APIs for drug candidates is closely associated with the development state of clinical research. As discussed above, while outsourcing of API manufacturing for early phase drug candidates might decrease, contract manufacturing of APIs for late stage drug candidates would increase instead.
On the other hand, demands for contract manufacturing of APIs for marketed drugs (including generic drugs) would likely become even stronger as more and more companies are forced to conduct cost reduction in every aspect of their operation under the extreme financial situation. Another positive factor is the recent opening of the FDA’s China offices (FDA now has offices in three Chinese cities). The presence of the FDA in China will certainly ignite the new hope for outsourcing companies as more, strict regulations and inspections will be expected to all Chinese CMOs that provide APIs or contract manufacturing services to the Western companies.
In summary, the current global financial crisis would exert a negative impact on the entire China pharma outsourcing industry. However, the degree of net effects varies from sector to sector. The early stage drug discovery and development would likely be hit hardest, whereas the late stage drug development including the CMO service sector would likely not be affected at all.